Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -19.34% is 65% above its 5-year average of -54.83%, near the high end of its 5-year range (-124.41%–-10.26%).
17.56% above its 12-month average of -23.46%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -27.16%.
NET PROFIT MARGIN
-19.34%
NET PROFIT MARGIN AVG TTM
-23.46%
NET PROFIT MARGIN AVG 3Y
-32.23%
NET PROFIT MARGIN AVG 5Y
-54.83%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+17.56%
CURRENT VS 3Y AVG
+40.00%
CURRENT VS 5Y AVG
+64.72%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-5425.71%
vs the sector median at left
NeuroPace, Inc.
Market Cap
$431.97M
Net Profit Margin
-19.34%
TTM Avg
-23.46%
3Y Avg
-32.23%
5Y Avg
-54.83%
Market Cap
$435.61M
Net Profit Margin
-1392.61%
TTM Avg
-834.59%
3Y Avg
-416.33%
5Y Avg
-277.55%
Market Cap
$426.51M
Net Profit Margin
-184.24%
TTM Avg
-97.14%
3Y Avg
-46011.59%
5Y Avg
-30736.66%
Market Cap
$438.07M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$439.55M
Net Profit Margin
-0.06%
TTM Avg
-74.67%
3Y Avg
-251.03%
5Y Avg
-526.51%
Market Cap
$424.10M
Net Profit Margin
-6.77%
TTM Avg
-13.38%
3Y Avg
-17.48%
5Y Avg
-11.79%
Market Cap
$422.86M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$422.72M
Net Profit Margin
-12.90%
TTM Avg
-139.82%
3Y Avg
-135.58%
5Y Avg
-114.97%
Market Cap
$442.34M
Net Profit Margin
-2178.90%
TTM Avg
-2455.14%
3Y Avg
-5466.68%
5Y Avg
-3741.67%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroPace, Inc. (NPCE) | $431.97M | -19.34% | -23.46% | -32.23% | -54.83% |
| YD Bio Limited Ordinary Shares (YDES)vs › | $435.61M | -1392.61% | -834.59% | -416.33% | -277.55% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | -184.24% | -97.14% | -46011.59% | -30736.66% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | 0.00% | 0.00% | 0.00% | 0.00% |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | -0.06% | -74.67% | -251.03% | -526.51% |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | -6.77% | -13.38% | -17.48% | -11.79% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | 0.00% | 0.00% | 0.00% | 0.00% |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | -12.90% | -139.82% | -135.58% | -114.97% |
| Ovid Therapeutics Inc. (OVID)vs › | $442.34M | -2178.90% | -2455.14% | -5466.68% | -3741.67% |
| Prothena Corporation plc (PRTA)vs › | $419.87M | -80.67% | -1305.53% | -747.23% | -2664.22% |
Operating Margin
-15.3%
Net Profit Margin
-19.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -27.16% |
| 2026-03-31 | -30.31% |
| 2025-12-31 | -10.26% |
| 2025-09-30 | -12.78% |
| 2025-06-30 | -36.78% |
| 2025-03-31 | -29.25% |
| 2024-12-31 | -24.46% |
| 2024-09-30 | -25.89% |
| 2024-06-30 | -39.02% |
| 2024-03-31 | -49.24% |
| 2023-12-31 | -34.42% |
| 2023-09-30 | -44.18% |
| 2023-06-30 | -55.26% |
| 2023-03-31 | -71.69% |
| 2022-12-31 | -87.15% |
| 2022-09-30 | -105.63% |
| 2022-06-30 | -124.41% |
| 2022-03-31 | -100.76% |
| 2021-12-31 | -97.24% |
| 2021-09-30 | -78.18% |
| 2021-06-30 | -67.25% |
| 2021-03-31 | -78.54% |
| 2020-12-31 | -42.95% |
| 2020-09-30 | -32.31% |
| 2020-06-30 | -115.09% |
| 2020-03-31 | -67.58% |
